Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
2h
NanoViricides, Inc. Has Filed its Quarterly Report – Subsequent Raise Has Fortified Fiscal Position
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...
SAS Viya Essentials rapidly deploys select SAS Viya products using SAS Managed Cloud Services Thursday, 20 November 2025 - SAS, a global ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion ...
The Biotech Growth Trust PLC - Half-year Financial Report ...
The majority of promotional expenditures are invested in drug samples, one of the industry’s most important marketing tactics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback